Abstract: A battery pack includes a battery pack box with an internal space including a first region to an n-th region, each provided with a battery cell. A positive electrode active substance in a positive electrode of each k-th battery cell includes lithium iron phosphate and/or lithium nickel cobalt manganate having a first discharge voltage plateau and one or more types of supplementary active substances having a second discharge voltage plateau. For the first battery cell to the n-th battery cell, in any case where a sum of a discharge capacity corresponding to the first discharge voltage plateau and a discharge capacity corresponding to the second discharge voltage plateau is 100%, a discharge capacity proportion corresponding to the second discharge voltage plateau of the k-th battery cell is greater than a discharge capacity proportion corresponding to the second discharge voltage plateau of the (k?1)-th battery cell.

Abstract: A battery pack includes a first battery cell, a second battery cell, and a third battery cell. A positive electrode active substance of each battery cell is composed of lithium iron phosphate and a low-temperature additive. The low-temperature additive is selected from compounds containing at least two carbonyl groups, which are conjugated with an unsaturated structure or an atom having lone-pair electrons connected with the carbonyl groups, and a discharging cut-off voltage of the battery pack at a low temperature has the following rules: discharging cut-off voltages V1, V2, and V3 of the first battery cell, second battery cell, and third battery cell range from 1.95V to 2.1V, from 1.8 V to 2.0V, from 1.6V to 1.9V, respectively, and V1, V2, and V3 satisfy a relationship of V1>V2>V3.

Abstract: An index update method, including: receiving an index update request, where the index update request is used to instruct to create or delete a target index that is associated with a field in a logic table of a tenant; updating metadata information of the logic table in a database in response to the index update request; notifying a coordination service, where the coordination service is used to notify a second data access node to perform a local synchronization update; and after all second data access nodes finish local synchronization updates, performing a data asynchronization update. After the metadata information is updated in the database, an index is updated in two steps. In a first step, a local synchronization update is performed. In a second step, after all data access nodes finish local synchronization updates, a data asynchronization update is performed.

Abstract: An index update method, including: receiving an index update request, where the index update request is used to instruct to create or delete a target index that is associated with a field in a logic table of a tenant; updating metadata information of the logic table in a database in response to the index update request; notifying a coordination service, where the coordination service is used to notify a second data access node to perform a local synchronization update; and after all second data access nodes finish local synchronization updates, performing a data asynchronization update. After the metadata information is updated in the database, an index is updated in two steps. In a first step, a local synchronization update is performed. In a second step, after all data access nodes finish local synchronization updates, a data asynchronization update is performed.

Abstract: An index update method, including: receiving an index update request, where the index update request is used to instruct to create or delete a target index that is associated with a field in a logic table of a tenant; updating metadata information of the logic table in a database in response to the index update request; notifying a coordination service, where the coordination service is used to notify a second data access node to perform a local synchronization update; and after all second data access nodes finish local synchronization updates, performing a data asynchronization update. After the metadata information is updated in the database, an index is updated in two steps. In a first step, a local synchronization update is performed. In a second step, after all data access nodes finish local synchronization updates, a data asynchronization update is performed.

Abstract: A query optimization method performed by a data access node includes: receiving a query request that is used to query tenant data; searching for a cached optimal query plan for the query request; if the optimal query plan is found, using the optimal query plan as a target query plan; or if no optimal query plan is found, generating a target query plan corresponding to the query request; and submitting the target query plan to a database, where the target query plan is used by the database to query the tenant data. Logical access (query request) is converted into a query plan (physical data access) by the data access node rather than a database node. In addition, the optimal query plan is used for query, so as to reduce a query cost as much as possible, and improve query performance.

Abstract: Embodiments of the present invention provide a column-oriented database processing method, where a column-oriented database includes a marker column and more than one data column, the data column is used to store specific data in a column store manner, a value of a marker bit of each row in the marker column is used to indicate validity of data that is located in a same row as the marker bit, and the method includes: receiving a query request sent by an application program, where the query request contains a query condition; querying the more than one data column according to the marker column and the query condition to obtain a query result that meets both the query condition and a requirement that a marker bit of the query result in the marker column is valid; and sending the query result to the application program.

Abstract: Embodiments of the present invention provide a column-oriented database processing method, where a column-oriented database includes a marker column and more than one data column, the data column is used to store specific data in a column store manner, a value of a marker bit of each row in the marker column is used to indicate validity of data that is located in a same row as the marker bit, and the method includes: receiving a query request sent by an application program, where the query request contains a query condition; querying the more than one data column according to the marker column and the query condition to obtain a query result that meets both the query condition and a requirement that a marker bit of the query result in the marker column is valid; and sending the query result to the application program.

Abstract: The invention provides novel polynucleotides and polypeptides encoded by such polynucleotides and mutants or variants thereof that correspond to a novel human secreted CD84-like polypeptide. These polynucleotides comprise nucleic acid sequences isolated from cDNA library from human spleen (Hyseq clone identification numbers 2938352 (SEQ ID NO: 1)). Other aspects of the invention include vectors containing processes for producing novel human secreted CD84-like polypeptides, and antibodies specific for such polypeptides.

Abstract: The invention provides novel polynucleotides and polypeptides encoded by such polynucleotides and mutants or variants thereof that correspond to a novel human secreted CD84-like polypeptide. These polynucleotides comprise nucleic acid sequences isolated from cDNA library from human spleen (Hyseq clone identification numbers 2938352 (SEQ ID NO: 1)). Other aspects of the invention include vectors containing processes for producing novel human secreted CD84-like polypeptides, and antibodies specific for such polypeptides.

Abstract: The present invention relates to newly identified nucleic acid molecules and polypeptides present in normal and neoplastic ovarian cells, including fragments, variants and derivatives of the nucleic acids and polypeptides. The present invention also relates to antibodies to the polypeptides of the invention, as well as agonists and antagonists of the polypeptides of the invention. The invention also relates to compositions containing the nucleic acid molecules, polypeptides, antibodies, agonists and antagonists of the invention and methods for the use of these compositions. These uses include identifying, diagnosing, monitoring, staging, imaging and treating ovarian cancer and noncancerous disease states in ovarian, identifying ovarian tissue, monitoring and identifying and/or designing agonists and antagonists of polypeptides of the invention. The uses also include gene therapy, production of transgenic animals and cells, and production of engineered ovarian tissue for treatment and research.

Abstract: The invention provides novel polynucleotides and polypeptides encoded by such polynucleotides and mutants or variants thereof that correspond to a novel human secreted CD84-like polypeptide. These polynucleotides comprise nucleic acid sequences isolated from cDNA library from human spleen (Hyseq clone identification numbers 2938352 (SEQ ID NO: 1)). Other aspects of the invention include vectors containing processes for producing novel human secreted CD84-like polypeptides, and antibodies specific for such polypeptides.

Abstract: The invention provides novel polynucleotides and polypeptides encoded by such polynucleotides and mutants or variants thereof that correspond to a novel human secreted CD84-like polypeptide. These polynucleotides comprise nucleic acid sequences isolated from cDNA library from human spleen (Hyseq clone identification numbers 2938352 (SEQ ID NO: 1)). Other aspects of the invention include vectors containing processes for producing novel human secreted CD84-like polypeptides, and antibodies specific for such polypeptides.

Abstract: The invention provides novel polynucleotides and polypeptides encoded by such polynucleotides and mutants or variants thereof that correspond to a novel human secreted CD84-like polypeptide. These polynucleotides comprise nucleic acid sequences isolated from cDNA library from human spleen (Hyseq clone identification numbers 2938352 (SEQ ID NO: 1)). Other aspects of the invention include vectors containing processes for producing novel human secreted CD84-like polypeptides, and antibodies specific for such polypeptides.

Abstract: The invention provides novel polynucleotides and polypeptides encoded by such polynucleotides and mutants or variants thereof that correspond to a novel human secreted CD84-like polypeptide. These polynucleotides comprise nucleic acid sequences isolated from cDNA library from human spleen (Hyseq clone identification numbers 2938352 (SEQ ID NO: 1)). Other aspects of the invention include vectors containing processes for producing novel human secreted CD84-like polypeptides, and antibodies specific for such polyeptides.

Abstract: The present invention relates to newly identified nucleic acids and polypeptides present in normal and neoplastic colon cells, including fragments, variants and derivatives of the nucleic acids and polypeptides. The present invention also relates to antibodies to the polypeptides of the invention, as well as agonists and antagonists of the polypeptides of the invention. The invention also relates to compositions comprising the nucleic acids, polypeptides, antibodies, variants, derivatives, agonists and antagonists of the invention and methods for the use of these compositions. These uses include identifying, diagnosing, monitoring, staging, imaging and treating colon cancer and non-cancerous disease states in colon tissue, identifying colon tissue, monitoring and identifying and/or designing agonists and antagonists of polypeptides of the invention. The uses also include gene therapy, production of transgenic animals and cells, and production of engineered colon tissue for treatment and research.

Abstract: The invention provides novel polynucleotides and polypeptides encoded by such polynucleotides and mutants or variants thereof that correspond to a novel human secreted stem cell growth factor-like polypeptide. These polynucleotides comprise nucleic acid sequences isolated from cDNA libraries prepared from human fetal liver spleen, ovary, adult brain, lung tumor, spinal cord, cervix, ovary, endothelial cells, umbilical cord, lymphocyte, lung fibroblast, fetal brain, and testis. Other aspects of the invention include vectors containing processes for producing novel human secreted stem cell growth factor-like polypeptides, and antibodies specific for such polypeptides.

Abstract: The present invention relates to newly identified nucleic acids and polypeptides present in normal and neoplastic breast cells, including fragments, variants and derivatives of the nucleic acids and polypeptides. The present invention also relates to antibodies to the polypeptides of the invention, as well as agonists and antagonists of the polypeptides of the invention. The invention also relates to compositions comprising the nucleic acids, polypeptides, antibodies, variants, derivatives, agonists and antagonists of the invention and methods for the use of these compositions. These uses include identifying, diagnosing, monitoring, staging, imaging and treating breast cancer and non-cancerous disease states in breast tissue, identifying breast tissue, monitoring and identifying and/or designing agonists and antagonists of polypeptides of the invention. The uses also include gene therapy, production of transgenic animals and cells, and production of engineered breast tissue for treatment and research.

Abstract: The present invention provides novel nucleic acids, novel polypeptide sequences encoded by these nucleic acids and uses thereof.

Abstract: The present invention provides novel nucleic acids, novel polypeptide sequences encoded by these nucleic acids and uses thereof.